Research programme: vaccines - Panacea Biotec

Drug Profile

Research programme: vaccines - Panacea Biotec

Alternative Names: 13-Valent pneumococcal vaccine - Panacea Biotec; 15-Valent pneumococcal vaccine - Panacea Biotec; Dengue vaccine - Panacea Biotec; DTaP - Panacea Biotec; DTaP-HIB-TT-HepB-IPV - Panacea Biotec; DTaP-HIB-TT-IPV - Panacea Biotec; Hapy3; Hapyfive; Hapysix; Inactivated JEV vaccine - Panacea Biotec; Influenza virus vaccine universal - Panacea Biotec; Japanese encephalitis vaccine - Panacea Biotec; Live-attenuated dengue vaccine - Panacea Biotec; Measles vaccine - Panacea Biotec; Meninogococcal vaccine - Panacea Biotec; Neisseria meningitidis vaccine tetravalent - Panacea Biotec; Pneumococcal conjugate CRM vaccine; rDen-delta-30 NIH vaccine - Panacea Biotec; Recombinant influenza virus vaccine universal - Panacea Biotec; Recombinant tetravalent dengue vaccine - Panacea Biotec; Tetravalent meningococcal vaccine - Panacea Biotec; Universal influenza virus vaccine - Panacea Biotec

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panacea Biotec; PT Bio Farma
  • Developer National Institute of Immunology; Panacea Biotec
  • Class Bacterial vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pneumococcal infections

Highest Development Phases

  • Preclinical Dengue; Influenza virus infections; Japanese encephalitis; Meningococcal infections; Pneumococcal infections
  • No development reported Measles

Most Recent Events

  • 07 Mar 2017 Panacea Biotec plans a phase I/II trial of Dengue tetravalent vaccine in healthy volunteers in India (CTRI2017-02-007923)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Measles in India (IM, Injection)
  • 20 Feb 2014 Research programme: pneumococcal vaccines - Panacea Biotec is available for licensing as of 01 Jan 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top